Our Mission

The mission of PPMI is to identify one or more biomarkers of Parkinson’s disease progression. The discovery of a biomarker is a critical step in the development of new and better treatments for PD. This study is being sponsored by The Michael J. Fox Foundation for Parkinson's Research.

PPMI Enrollment Status

Prodromal Participants
Enrollment Goal: 100

Genetic Cohort Participants
Enrollmen Goal: 600

Genetic Registry Participants
Enrollment Goal: ~600

De Novo PD Participants
Enrollment Goal: 400

Control Participants
Enrollment Goal: 200

Subjects with SWEDD
Enrollment: 64

Last Update: August 26, 2014


More about study cohorts >


Welcome to the Parkinson’s Progression Markers Initiative (PPMI), a landmark observational clinical study to comprehensively evaluate cohorts of significant interest using advanced imaging, biologic sampling and clinical and behavioral assessments to identify biomarkers of Parkinson’s disease progression.

PPMI is taking place at clinical sites in the United States, Europe, Israel, and Australia. Data and samples acquired from study participants will enable the development of a comprehensive Parkinson’s database and biorepository, which is currently available to the scientific community to conduct field-changing research.

PPMI is made possible by the concerted efforts of a number of collaborators. This study is sponsored by The Michael J. Fox Foundation for Parkinson’s Research.

Learn more about Who We Are.


Core Focus: the Genetics Coordination Core

The PPMI study cores are responsible for a wide range of study needs including analyzing, storing, and performing quality control measures on the study data and specimens, providing supplies, guidance, and support to study sites, and performance and study management. In this core spotlight, Genetics Coordination Core Principal Investigator Tatiana Foroud, PhD and her team explain their role in PPMI.

Understanding the Genetic Widespread Recruitment Initiative

The Widespread Recruitment Initiative (WRI) is an internet-based recruitment tool that allows potential PPMI participants to be screened, consented and provided with LRRK2 testing without having to visit a PPMI site. Find out how the process works.

Publication Associates RBD with Worse Motor Symptoms in PD

New research from Johns Hopkins University using PPMI baseline data from Parkinson’s patients has found that those experiencing REM sleep behavior disorder (RBD) symptoms have more severe motor symptoms than patients without RBD. The findings were published in the journal Tremor and Other Hyperkinetic Movements.

Funding and Biospecimens Access Opportunity

The Michael J. Fox Foundation for Parkinson’s Research has supported several pre-clinical and clinical efforts that have generated valuable data, biospecimens, and tissue resources for the research community. Qualified researchers may request access to these resources (including PPMI) with or without funding requests by using a single application through Access Data & Biospecimens. Deadline: August 11. Informational call: July 28.

MDS 2014 PPMI Presentations are Live

The PPMI presentations and posters from the International Parkinson and Movement Disorders Society’s 18th annual congress are now available in Presentations.

Learn More